Glenn Lab in the division of Gastroenterology & Hepatology



The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy
Pang PS, Planet PJ, Glenn JS.
PLos One. 2009;4(8):e6579

Alpha-helical peptide-induced vesicle rupture revealing new insight into the vesicle fusion process as monitored in situ by quartz crystal microbalance-dissipation and reflectometry.
Cho NJ, Wang G, Edvardsson M, Glenn JS, Hook F, Frank CW.
Anal Chem. 2009 Jun 15;81(12):4752-61.

The anti-hepatitis C agent nitazoxanide induces phosphorylation of elF2alpha via PKR activation.
Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, Rossignol JF, Glenn JS.
Gastroenterology. 2009

Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel.
Cho NJ, Elazar M, Xiong A, Lee W, Chiao E, Baker J, Frank CW, Glenn JS.
Biomed Mater. 2009 Feb;4(1):11001.

Isolation of human fetal liver progenitors and their enhanced proliferation by three-dimensional coculture with endothelial cells.
Xiong A, Austin TW, Lagasse E, Uchida N, Tamaki S, Bordier BB, Weissman IL, Glenn JS, Millan MT.
Tissue Eng Part A. 2008 Jun;14(6):995-1006.

Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis.
Einav S, Gerber D, Bryson PD, Sklan EH, Elazar M, Maerkl SJ, Glenn JS, Quake SR.
Nat Biotechnol. 2008;26(9):1019-27

Isolation and transcriptional profiling of purified hepatic cells derived from human embryonic stem cells.
Chiao E, Elazar M, Xing Y, Xiong A, Kmet M, Millan MT, Glenn JS, Wong WH, Baker J.Stem Cells. 2008 Aug;26(8):2032-41. Epub 2008 Jun 5

The nucleotide binding motif of hepatitis C virus NS4B can mediate cellular transformation and tumor formation without Ha-ras co-transfection.
Einav S, Sklan EH, Moon HM, Gehrig E, Liu P, Hao Y, Lowe AW, Glenn JS.
Hepatology. 2008 Mar;47(3):827-35.

Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS.
Antimicrob Agents Chemother. 2008 Nov;52(11):4069-71. Epub 2008 Aug 18.

Isolation of Human Fetal Liver Progenitors and Their Enhanced Proliferation by Three-Dimensional Coculture with Endothelial Cells.
Xiong A, Austin TW, Lagasse E, Uchida N, Tamaki S, Bordier BB, Weissman IL, Glenn JS, Millan MT.Tissue Eng Part A. 2008 Apr 23.

TBC1D20 is a Rab1 GTPase-activating protein that mediates hepatitis C virus replication.
Sklan EH, Serrano RL, Einav S, Pfeffer SR, Lambright DG, Glenn JS.
J Biol Chem. 2007 Dec 14;282(50):36354-61. Epub 2007 Sep 27.

Binding dynamics of hepatitis C virus' NS5A amphipathic peptide to cell and model membranes.
Cho NJ, Cheong KH, Lee C, Frank CW, Glenn JS.
J Virol. 2007 Jun;81(12):6682-9. Epub 2007 Apr 11.

Hepatitis d.
Koytak ES, Yurdaydin C, Glenn JS.
Curr Treat Options Gastroenterol. 2007 Dec;10(6):456-63.

Employing an amphipathic viral peptide to create a lipid bilayer on Au and TiO2.
Cho NJ, Cho SJ, Cheong KH, Glenn JS, Frank CW.
J Am Chem Soc. 2007 Aug 22;129(33):10050-1. Epub 2007 Jul 28. No abstract available.

The Power of silence: application of small interfering RNAs to gastrointestinal diseases.
Sklan EH, Glenn JS.
Gastroenterology. 2007 Jun;132(7):2291-5. Review. No abstract available

Creation of lipid partitions by deposition of amphipathic viral peptides.
Cho NJ, Cho SJ, Hardesty JO, Glenn JS, Frank CW.
Langmuir. 2007 Oct 9;23(21):10855-63. Epub 2007 Sep 6.

Employing two different quartz crystal microbalance models to study changes in viscoelastic behavior upon transformation of lipid vesicles to a bilayer on a gold surface.
Cho NJ, Kanazawa KK, Glenn JS, Frank CW.
Anal Chem. 2007 Sep 15;79(18):7027-35. Epub 2007 Aug 8.

A Rab-GAP TBC domain protein binds hepatitis C virus NS5A and mediates viral replication.
Sklan EH, Staschke K, Oakes TM, Elazar M, Winters M, Aroeti B, Danieli T, Glenn JS.
J Virol. 2007 Oct;81(20):11096-105. Epub 2007 Aug 8.

Prenylation of HDAg and antiviral drug development.
Glenn JS.
Curr Top Microbiol Immunol. 2006;307:133-49. Review.

Molecular virology of the hepatitis C virus: implication for novel therapies.
Glenn JS.
Infect Dis Clin North Am. 2006 Mar;20(1):81-98.

Molecular virology of the hepatitis C virus: implication for novel therapies.
Glenn JS.
Clin Liver Dis. 2005 Aug;9(3):353-69, v. Review.

Novel therapies for hepatitis C virus based on lessons from virology.
Glenn JS.
Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S86-8. Review.

Hepatitis C virus core protein associates with detergent-resistant membranes distinct from classical plasma membrane rafts.
Matto M, Rice CM, Aroeti B, Glenn JS.
J Virol. 2004 Nov;78(21):12047-53.

An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication.
Elazar M, Liu P, Rice CM, Glenn JS.
J Virol. 2004 Oct;78(20):11393-400.

A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication.
Einav S, Elazar M, Danieli T, Glenn JS.
J Virol. 2004 Oct;78(20):11288-95.

Overdependence on the host-an Achilles' heel of HCV?
Glenn JS.
Hepatology. 2004 Jun;39(6):1734-5. No abstract available.

Testing antivirals against hepatitis delta virus: farnesyl transferase inhibitors.
Bordier BB, Glenn JS.
Methods Mol Med. 2004;96:539-53. No abstract available.

Amphipathic helix-dependent localization of NS5A mediates hepatitis C virus RNA replication.
Elazar M, Cheong KH, Liu P, Greenberg HB, Rice CM, Glenn JS.
J Virol. 2003 May;77(10):6055-61.

In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus.
Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, Meuse L, Kay MA, Casey JL, Sebti SM, Hamilton AD, Glenn JS.
J Clin Invest. 2003 Aug;112(3):407-14.

Prenylation inhibitors: a novel class of antiviral agents.
Einav S, Glenn JS.
J Antimicrob Chemother. 2003 Dec;52(6):883-6. Epub 2003 Nov 12. Review.

A prenylation inhibitor prevents production of infectious hepatitis delta virus particles.
Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, Glenn JS.
J Virol. 2002 Oct;76(20):10465-72.

Sustained survival of human hepatocytes in mice: A model for in vivo infection with human hepatitis B and hepatitis delta viruses.
Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA.
Nat Med. 2000 Mar;6(3):327-31.

Use of a prenylation inhibitor as a novel antiviral agent.
Glenn JS, Marsters JC Jr, Greenberg HB.
J Virol. 1998 Nov;72(11):9303-6.

Finding the iron in the melting pot--practical use of a new genetic assay for hereditary hemochromatosis.
Glenn JS, Cheung RC.
West J Med. 1998 Jun;168(6):525-7. No abstract available.

Identification of a prenylation site in delta virus large antigen.
Glenn JS, Watson JA, Havel CM, White JM.
Science. 1992 May 29;256(5061):1331-3.



Footer Links: